Skip to main content
Fig. 2 | Thrombosis Journal

Fig. 2

From: Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study

Fig. 2

The Hazard Plots (Kaplan Meier) for: a TE events, (b) Major Haemorrhage for the first 12 months of follow-up of 82 patients on IDPTP. c Incidence of thrombembolic events (TE) and Major Bleeding at different time periods. A lower incidence of TE is seen during the 1st 3 months, 0.4% (95% CI 0.0, 2.4; 1/226 subject months), compared to 2.1% (95% CI 0.4, 5.9; 3/146 subject months) after 8 months (the median duration of thromboprophylaxis in this group). A similar pattern is notable for major bleeding. Incidence was less in the 1st 3 months, 0.9% (95% CI 0.1, 3.1; 2/227 subject months). During the 4–8 months period (280 subject months), 5 patients experienced a major bleeding event that gives an incidence of 1.8% (95% CI 0.6, 4.1). Comparable to that, 3 patients (146 subject months) had major bleed after 8 months with an incidence of 2.1% (95% CI 0.4, 5.9)

Back to article page